Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Chimerix, Inc. (NASDAQ: CMRX).

Full DD Report for CMRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CMRX)

New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Q2 Holdings, Inc. (NYSE:QTWO), BioTime, Inc. (NYSE:BTX), Verastem, Inc...
Source: GlobeNewswire
Date: December, 03 2018 07:55
Chimerix to Present at the Stifel 2018 Healthcare Conference
DURHAM, N.C., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H., Chief Executive Officer and Tim Tro...
Source: GlobeNewswire
Date: November, 07 2018 08:13
Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018
DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, November 8, 2018 at...
Source: GlobeNewswire
Date: November, 01 2018 08:00
Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology - Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Univar Inc. (NYSE:UNVR), Aqua America, Inc. (NYSE:WTR), Chimerix, Inc. (N...
Source: GlobeNewswire
Date: October, 24 2018 07:25
Key events next week - healthcare
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 12 2018 08:52
Chimerix to Host Annual Investor Update on October 17, 2018
DURHAM, N.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host the Company's annual investor update on October 17, 2018, at 4:30 p.m. ET in New Y...
Source: GlobeNewswire
Date: October, 11 2018 16:01
Chimerix presents results from multiple ascending dose study of IV BCV at IDWeek
Chimerix (NASDAQ: CMRX ) announces data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of intravenous (IV) brincidofovir (BCV) in healthy subjects. These data will be presented at IDWeek, held October 3-7 in Sa...
Source: SeekingAlpha
Date: October, 05 2018 07:38
Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
DURHAM, N.C., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascendin...
Source: GlobeNewswire
Date: October, 05 2018 07:00
Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
DURHAM, N.C., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the full analysis of adenovirus (AdV) viral load dynamics and all-cause mortality in pediatric patients. These da...
Source: GlobeNewswire
Date: October, 04 2018 07:00
Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference
DURHAM, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will...
Source: GlobeNewswire
Date: September, 26 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-133.3853.363.413.30119,050
2018-12-123.483.433.533.405135,206
2018-12-113.453.443.5113.37204,585
2018-12-103.303.3553.433.2581,701
2018-12-073.173.263.303.17185,435

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-136,83518,29137.3681Short
2018-12-1218,22537,20448.9867Short
2018-12-113,88361,5686.3068Cover
2018-12-101,35420,7526.5247Cover
2018-12-072,93225,01711.7200Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CMRX.


About Chimerix, Inc. (NASDAQ: CMRX)

Logo for Chimerix, Inc. (NASDAQ: CMRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CMRX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 07 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 05 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 01 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 01 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 01 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: CMRX)

      Daily Technical Chart for (NASDAQ: CMRX)


      Stay tuned for daily updates and more on (NASDAQ: CMRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CMRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CMRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CMRX and does not buy, sell, or trade any shares of CMRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/